Patient info Open main menu

Lamictal 25 mg dispersible/chewable tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

Medicine strength:
25 mg
Other strengths and forms:
Contains active substance:
ATC code:
Similar medicines:

Sources: Original (products.mhra.gov.uk)

Summary of Product Characteristics (SmPC) - Lamictal 25 mg dispersible/chewable tablets

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Not applicable

4.2. Posology and method of administration

Not applicable

4.3. Contrain­dications

Not applicable

4.4. Special warnings and precautions for use

Not applicable

4.5. Interactions with other medicinal products and other forms of interaction

Not applicable

4.6. Pregnancy and lactation

Not applicable

4.7. Effects on ability to drive and use machines

Not applicable

4.8. Undesirable effects

Not applicable

4.9. Overdose

Not applicable

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmaco­dynamic properties

Not applicable

5.2. Pharmaco­kinetic properties

Not applicable

5.3. Preclinical safety data

Not applicable

Sources: Original (products.mhra.gov.uk)

Facts about Lamictal 25 mg dispersible/chewable tablets

Active substance Lamotrigine
Strength 25 mg
Drug group (ATC)
  1. N Nervous system drugs
    1. N03 Antiepileptics
      1. N03A Antiepileptics
        1. N03AX Other antiepileptics
          1. N03AX09 lamotrigine
Marketing authorisation PLPI 18799/2171

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.